Rocket Pharmaceuticals Seen With Continued Progress in 2026 -- Market Talk

Dow Jones01-03

1206 ET - Rocket Pharmaceuticals will likely continue to make slow progress over the course of this year, giving shares a boost, Cantor Fitzgerald analyst Josh Schimmer says in a note. Investors have generally turned away from the gene therapy field due to setbacks related to capsid technology, Schimmer says. But "hope is not lost, certainly for RCKT," he says. The company is addressing significant unmet medical needs as it moves forward with three late-stage programs, he says, noting he continues to hold the management team in high regard. "The company isn't out of the woods, but success with any of its cardio programs would likely drive shares considerably higher from current levels," he says, reiterating his overweight rating on the stock. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

January 02, 2026 12:06 ET (17:06 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2600064651?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-03 01:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600064651","market":"sg","top_or_hot":-1,"title":"Rocket Pharmaceuticals Seen With Continued Progress in 2026 -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1206 ET - Rocket Pharmaceuticals will likely continue to make slow progress over the course of this year, giving shares a boost, Cantor Fitzgerald analyst Josh Schimmer says in a note. Investors have generally turned away from the gene therapy field due to setbacks related to capsid technology, Schimmer says. But \"hope is not lost, certainly for RCKT,\" he says. The company is addressing significant unmet medical needs as it moves forward with three late-stage programs, he says, noting he continues to hold the management team in high regard. \"The company isn't out of the woods, but success with any of its cardio programs would likely drive shares considerably higher from current levels,\" he says, reiterating his overweight rating on the stock. (kelly.cloonan@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 02, 2026 12:06 ET (17:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rocket Pharmaceuticals Seen With Continued Progress in 2026 -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRocket Pharmaceuticals Seen With Continued Progress in 2026 -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-03 01:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1206 ET - Rocket Pharmaceuticals will likely continue to make slow progress over the course of this year, giving shares a boost, Cantor Fitzgerald analyst Josh Schimmer says in a note. Investors have generally turned away from the gene therapy field due to setbacks related to capsid technology, Schimmer says. But \"hope is not lost, certainly for RCKT,\" he says. The company is addressing significant unmet medical needs as it moves forward with three late-stage programs, he says, noting he continues to hold the management team in high regard. \"The company isn't out of the woods, but success with any of its cardio programs would likely drive shares considerably higher from current levels,\" he says, reiterating his overweight rating on the stock. (kelly.cloonan@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 02, 2026 12:06 ET (17:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RCKT","symbol_name":"Rocket Pharmaceuticals, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2600064651","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600064651","pubTimestamp":1767373560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1206 ET - Rocket Pharmaceuticals will likely continue to make slow progress over the course of this year, giving shares a boost, Cantor Fitzgerald analyst Josh Schimmer says in a note. Investors have generally turned away from the gene therapy field due to setbacks related to capsid technology, Schimmer says. But \"hope is not lost, certainly for RCKT,\" he says. The company is addressing significant unmet medical needs as it moves forward with three late-stage programs, he says, noting he continues to hold the management team in high regard. \"The company isn't out of the woods, but success with any of its cardio programs would likely drive shares considerably higher from current levels,\" he says, reiterating his overweight rating on the stock. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RCKT":"Rocket Pharmaceuticals, Inc.","BK4097":"系统软件","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","PRGS":"Progress Software Corporation","BK4139":"生物科技"},"translate_title":"Rocket Pharmaceuticals有望在2026年继续取得进展——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RCKT":0.9,"PRGS":1.5},"content_text":"1206 ET - Rocket Pharmaceuticals will likely continue to make slow progress over the course of this year, giving shares a boost, Cantor Fitzgerald analyst Josh Schimmer says in a note. Investors have generally turned away from the gene therapy field due to setbacks related to capsid technology, Schimmer says. But \"hope is not lost, certainly for RCKT,\" he says. The company is addressing significant unmet medical needs as it moves forward with three late-stage programs, he says, noting he continues to hold the management team in high regard. \"The company isn't out of the woods, but success with any of its cardio programs would likely drive shares considerably higher from current levels,\" he says, reiterating his overweight rating on the stock. (kelly.cloonan@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2026 12:06 ET (17:06 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600064651","isCrawlerRequest":true}